Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants.

Objective: To evaluate the link between antidepressants and suicidal behavior and ideation (suicidality) in youth, adverse events from pediatric clinical trials were classified in order to identify suicidal events. The authors describe the Columbia Classification Algorithm for Suicide Assessment (C-...

Descripción completa

Detalles Bibliográficos
Publicado en:American Journal of Psychiatry Vol. 164; no. 7; pp. 1035 - 1044
Autores principales: Posner K, Oquendo MA, Gould M, Stanley B, Davies M, Posner, Kelly, Oquendo, Maria A, Gould, Madelyn, Stanley, Barbara, Davies, Mark
Formato: research tables/charts Journal Article
Publicado: American Psychiatric Publishing, Inc. Jul2007
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106201551&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 106201551
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        0002953X
        API
      jtl: American Journal of Psychiatry
      issn: 0002953X
      maglogo: N
    pubinfo:
      dt: Jul2007
      vid: 164
      iid: 7
      pid: 37323
      pub: American Psychiatric Publishing, Inc.
      place: Arlington, Virginia
    artinfo:
      ui:
        106201551
        106201551
        NLM17606655
        2009624402
        10.1176/ajp.2007.164.7.1035
        NLM17606655
        PMC3804920
        106201551
      ppf: 1035
      ppct: 9
      formats:
      tig:
        atl: Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants.
      aug:
        au:
          Posner K
          Oquendo MA
          Gould M
          Stanley B
          Davies M
          Posner, Kelly
          Oquendo, Maria A
          Gould, Madelyn
          Stanley, Barbara
          Davies, Mark
        affil: Division of Child and Adolescent Psychiatry, Columbia University/New York State Psychiatric Institute, New York, NY 10032, USA
      sug:
        subj:
          Algorithms
          Antidepressive Agents Adverse Effects
          Risk Assessment
          Suicide Classification
          United States Food and Drug Administration
          Adolescence
          Age Factors
          Antidepressive Agents Therapeutic Use
          Child
          Depression Drug Therapy
          Depression Psychosocial Factors
          Descriptive Statistics
          Female
          Funding Source
          Intraclass Correlation Coefficient
          Legislation, Drug
          Male
          Mental Disorders Drug Therapy
          Mental Disorders Psychosocial Factors
          Meta Analysis
          Nomenclature
          Pharmaceutical Companies
          Placebos
          Reproducibility of Results
          Risk Assessment Methods
          Suicide Psychosocial Factors
          Suicide, Attempted Classification
          Suicide, Attempted Psychosocial Factors
          United States
          Human
          Adolescent: 13-18 years
          Child: 6-12 years
          Female
          Male
      ab: Objective: To evaluate the link between antidepressants and suicidal behavior and ideation (suicidality) in youth, adverse events from pediatric clinical trials were classified in order to identify suicidal events. The authors describe the Columbia Classification Algorithm for Suicide Assessment (C-CASA), a standardized suicidal rating system that provided data for the pediatric suicidal risk analysis of antidepressants conducted by the Food and Drug Administration (FDA).Method: Adverse events (N=427) from 25 pediatric antidepressant clinical trials were systematically identified by pharmaceutical companies. Randomly assigned adverse events were evaluated by three of nine independent expert suicidologists using the Columbia classification algorithm. Reliability of the C-CASA ratings and agreement with pharmaceutical company classification were estimated.Results: Twenty-six new, possibly suicidal events (behavior and ideation) that were not originally identified by pharmaceutical companies were identified in the C-CASA, and 12 events originally labeled as suicidal by pharmaceutical companies were eliminated, which resulted in a total of 38 discrepant ratings. For the specific label of "suicide attempt," a relatively low level of agreement was observed between the C-CASA and pharmaceutical company ratings, with the C-CASA reporting a 50% reduction in ratings. Thus, although the C-CASA resulted in the identification of more suicidal events overall, fewer events were classified as suicide attempts. Additionally, the C-CASA ratings were highly reliable (intraclass correlation coefficient [ICC]=0.89).Conclusions: Utilizing a methodical, anchored approach to categorizing suicidality provides an accurate and comprehensive identification of suicidal events. The FDA's audit of the C-CASA demonstrated excellent transportability of this approach. The Columbia algorithm was used to classify suicidal adverse events in the recent FDA adult antidepressant safety analyses and has also been mandated to be applied to all anticonvulsant trials and other centrally acting agents and nonpsychotropic drugs.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N